Mahmood, U.; Josephides, E.; Coupe, N.; Smith, D.; Ahmad, S.; Al-Salihi, O.; Mak, S.M.; Chitnis, M.; Georgiou, A.; Ajzensztejn, D.;
et al. Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational Experience. Cancers 2026, 18, 71.
https://doi.org/10.3390/cancers18010071
AMA Style
Mahmood U, Josephides E, Coupe N, Smith D, Ahmad S, Al-Salihi O, Mak SM, Chitnis M, Georgiou A, Ajzensztejn D,
et al. Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational Experience. Cancers. 2026; 18(1):71.
https://doi.org/10.3390/cancers18010071
Chicago/Turabian Style
Mahmood, Umair, Eleni Josephides, Nicholas Coupe, Daniel Smith, Shahreen Ahmad, Omar Al-Salihi, Sze M. Mak, Meenali Chitnis, Alexandros Georgiou, Daniel Ajzensztejn,
and et al. 2026. "Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational Experience" Cancers 18, no. 1: 71.
https://doi.org/10.3390/cancers18010071
APA Style
Mahmood, U., Josephides, E., Coupe, N., Smith, D., Ahmad, S., Al-Salihi, O., Mak, S. M., Chitnis, M., Georgiou, A., Ajzensztejn, D., Karapanagiotou, E., Higgins, G. S., Panakis, N., Schoenfeld, J. D., & Skwarski, M.
(2026). Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational Experience. Cancers, 18(1), 71.
https://doi.org/10.3390/cancers18010071
